Samuel Kareff, MD
Hematology & Oncology · Delray Beach, FLNPI 1386149516
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 21.7%. 2025 is the largest year on record at $9,550, more than ten times the $328 reported in 2022.
Across 164 payments — averaging $89.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- Ipsen Biopharmaceuticals, Inc$2K
- Regeneron$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Daiichi Sankyo Inc.$842
- AstraZeneca$483
- plus $4K from 31 others
Across 5 payments — averaging $7082.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$35K
- Eli Lilly$478
What the payments were for
- Consulting fees$7,53752%
- Speaking & faculty fees$2,07014%
- Travel & lodging$1521%
- Food & beverage$4,20429%
- Education$6534%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 6 | $3,173 |
| Ipsen Biopharmaceuticals, Inc | 5 | $2,410 |
| Regeneron | 2 | $2,142 |
| Regeneron Healthcare Solutions, Inc. | 4 | $1,465 |
| Daiichi Sankyo Inc. | 10 | $842 |
| AstraZeneca(2 entities) | 16 | $483 |
| Johnson & Johnson(2 entities) | 21 | $409 |
| Lantheus Medical Imaging, Inc. | 1 | $392 |
| Pfizer | 10 | $365 |
| Genentech USA, Inc. | 7 | $302 |
| Seagen Inc. | 3 | $299 |
| Gilead(2 entities) | 6 | $285 |
| Bristol Myers Squibb | 9 | $273 |
| Array Biopharma Inc | 6 | $143 |
| Sanofi | 5 | $141 |
| Cardinal Health 110 LLC | 1 | $125 |
| Merck | 5 | $107 |
| Astellas Pharma US Inc | 2 | $105 |
| Novartis | 4 | $103 |
| E.r. Squibb & Sons, L.L.C. | 5 | $100 |
| Beigene USA, Inc. | 4 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $96 |
| Eisai Inc. | 3 | $77 |
| Adaptive Biotechnologies Corporation | 3 | $73 |
| Novocure Inc. | 2 | $73 |
| Exelixis Inc. | 3 | $65 |
| Sobi, Inc | 1 | $62 |
| Incyte Corporation | 2 | $58 |
| Karyopharm Therapeutics Inc. | 2 | $57 |
| Caris MPI, Inc. | 2 | $53 |
| GSK | 2 | $51 |
| Jazz Pharmaceuticals Inc. | 2 | $43 |
| EMD Serono, Inc. | 2 | $38 |
| Pharmaessentia USA Corporation | 1 | $31 |
| AVEO Pharmaceuticals, Inc. | 1 | $30 |
| Genentech, Inc. | 1 | $28 |
| Bayer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,616 in reported general payments places this provider in the 65th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Delray Beach
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
- Shahram MoriOrlando$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.